Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
This article was originally published in PharmAsia News
Executive Summary
A decision to withdraw Novartis' Prexige (lumiracoxib) in Australia after two patients died from serious liver injury following treatment with the drug is likely to impact the outcome of FDA's decision on a pending NDA for the COX-2 inhibitor